Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV anti CD40 HIV5 PEP vaccine - LinKinVax

Next Previous
X
Search
Drug Profile

HIV anti CD40 HIV5 PEP vaccine - LinKinVax

Alternative Names: HIV ANTI-CD40 HIV5-PEP

Latest Information Update: 23 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaccine Research Institute
  • Developer LinKinVax
  • Class Recombinant fusion proteins; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 14 Mar 2022 LinKinVax plans to launch HIV vaccine for HIV infections (Prevention) by 2027 (LinKinVax pipeline, March 2022)
  • 03 Feb 2022 LinKinVax entered an exclusive worldwide licensing agreement with Inserm Transfert to develop vaccine strategy for HIV, SARS-CoV-2, human papillomavirus-related cancers, and chlamydia infections
  • 02 Feb 2022 Early research in HIV infections (Treatment, Prevention) in France (Parenteral) prior to February 2022 (LinKinVax pipeline, March 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top